Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 28, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on July 25, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding the share buyback program. No revenue, profit, cash flow, or debt metrics are provided in this specific document.
- Shares Purchased (July 25, 2025): 488,010 ordinary shares
- Price Range (GBp): 1,387.00p (Low) to 1,398.00p (High)
- Volume-Weighted Average Price (GBp): 1,392.64p
- Total Shares Purchased Since June 4, 2025: 17,165,367 ordinary shares
- Treasury Shares Held: 235,299,750
- Ordinary Shares in Issue (excluding Treasury): 4,080,085,660
- Total Voting Rights: 4,080,085,660
- Treasury Share Voting Percentage: 5.77%
Material Changes
The filing reports a reduction in the number of shares outstanding due to the purchase of 488,010 shares on July 25, 2025. These shares are held as Treasury shares. The total number of shares purchased under the current program has increased to over 17 million since the program's inception on June 4, 2025.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results.
Investor Verification Checklist
- Verify the total remaining authorization under the share buyback program against the 17,165,367 shares purchased to date.
- Confirm the impact of the 5.77% treasury share holding on voting rights calculations for major shareholders.
- Review the non-discretionary agreement terms with Merrill Lynch International to understand the remaining duration and volume constraints of the buyback.
- Check the latest Form 20-F for updated risk factors referenced in the cautionary statement.